Applied Genetic Technologies Corporation

Applied Genetic Technologies Corporation
Company type	Public
Traded as	Nasdaq: AGTC; Russell Microcap Index component
Industry	Biotechnology
Founded	January 19, 1999; 25 years ago
Headquarters	Alachua, Florida, United States
Key people	Susan B. Washer; (president & CEO); William A. Sullivan (CFO);
Revenue	US$ 24.19 million; (FY JUN 30, 2018);
Operating income	US$ -22.38 million; (FY JUN 30, 2018);
Net income	US$ -21.30 million; (FY JUN 30, 2018);
Total assets	US$ 118.53 million; (FY JUN 30, 2018);
Total equity	US$ 99.18 million; (FY JUN 30, 2018);
Number of employees	78; (FY JUN 30, 2018);
Website	AGTC.com
	Footnotes / references;

The Applied Genetic Technologies Corporation is a publicly traded^[2] biotechnology company that is part of the NASDAQ Biotechnology Index. It was founded in 1999 and has its headquarters in Alachua, Florida.^[3] In late June 2019, the company announced the appointment of Global Clinical and Medical Affairs Veteran, Theresa G.H. Heah, M.D., M.B.A., to Join as Chief Medical Officer.^[4]

The company focuses on ophthalmologic genetic diseases. The company's technologies are aimed at products that might have the potential to treat achromatopsia, X-linked retinoschisis,^[5]^[6] X-linked retinitis pigmentosa,^[7] and age-related macular degeneration.^[8] The company has six products in various stages of development; as of 2016, none had yet been approved.^[9]

In January 2017, AGTC entered into a strategic research and development collaboration with Bionic Sight, an innovator in the emerging field of optogenetics and retinal coding. Through the collaboration, AGTC and Bionic Sight will to develop a new optogenetic therapy that leverages AGTC's deep experience in gene therapy and ophthalmology.^[10]

On January 9, 2020, the company reported positive results from a Phase 1/2 trial for its investigational gene therapy for retinitis pigmentosa.^[11] A few weeks later, the company reported interim six-month data from the dose-escalation cohorts of its ongoing Phase 1/2 clinical programs in patients with achromatopsia due to mutation in the ACHM CNGB3 or ACHM CNGA3 genes.^[12] Applied Genetic Technologies Corporation is a patient partner within the blinding eye disease and rare disease community, including organizations like Foundation for Fighting Blindness and Global Genes.^[13]

References

^ "US SEC: Form 10-K Applied Genetic Technologies Corporation". U.S. Securities and Exchange Commission. September 11, 2018. Retrieved December 1, 2018.
^ "Applied Genetic Technologies Corporation (AGTC)". NASDAQ.com. Retrieved 4 January 2016.
^ "Company Overview of Applied Genetic Technologies Corporation". Bloomberg. Retrieved November 15, 2016.
^ "AGTC Announces New Leadership Appointments". Applied Genetic Technologies Corporation. Retrieved 2020-03-26.
^ Chen, Angela. "Biogen to Pay Applied Genetic $124 Million to Develop Eye-Disease Treatments". Wall Street Journal. Retrieved 4 January 2016.
^ "AGTC Announces Data Evaluating the Natural History of Patients With X-Linked Retinoschisis at the 48th Annual Retina Society Meeting". Yahoo Finance. Retrieved 4 January 2016.^{[dead link‍]}
^ "Biogen enters eye-treatment arena with AGTC deal". Reuters. 2 July 2015. Retrieved 4 January 2016.
^ Ballie, Katherine. "Penn-Michigan State Team Develops Novel Gene Therapy for Achromatopsia". www.upenn.edu. Archived from the original on 27 October 2015. Retrieved 4 January 2016.
^ "Finding Cures for Visual Disorders l Products". www.agtc.com. Archived from the original on 5 January 2016. Retrieved 4 January 2016.
^ "Collaborations". agtc.com. Retrieved 2020-03-13.
^ Lee, Jaimy. "Applied Genetic Technologies' stock rockets on early-stage eye therapy data". MarketWatch. Retrieved 2020-02-25.
^ "AGTC Reports Encouraging Interim Six-Month Data from the Dose Escalation Cohorts of its Ongoing Phase 1/2 Clinical Trials in Achromatopsia". Applied Genetic Technologies Corporation. Retrieved 2020-03-04.
^ "Patient Partners". agtc.com. Retrieved 2020-04-02.

External links

Official website
Business data for AGTC:

This United States corporation or company article is a stub. You can help Wikipedia by expanding it.

[10K2018-1] "US SEC: Form 10-K Applied Genetic Technologies Corporation". U.S. Securities and Exchange Commission. September 11, 2018. Retrieved December 1, 2018.

[2] "Applied Genetic Technologies Corporation (AGTC)". NASDAQ.com. Retrieved 4 January 2016.

[bberg-3] "Company Overview of Applied Genetic Technologies Corporation". Bloomberg. Retrieved November 15, 2016.

[4] "AGTC Announces New Leadership Appointments". Applied Genetic Technologies Corporation. Retrieved 2020-03-26.

[5] Chen, Angela. "Biogen to Pay Applied Genetic $124 Million to Develop Eye-Disease Treatments". Wall Street Journal. Retrieved 4 January 2016.

[6] "AGTC Announces Data Evaluating the Natural History of Patients With X-Linked Retinoschisis at the 48th Annual Retina Society Meeting". Yahoo Finance. Retrieved 4 January 2016.^{[dead link‍]}

[7] "Biogen enters eye-treatment arena with AGTC deal". Reuters. 2 July 2015. Retrieved 4 January 2016.

[8] Ballie, Katherine. "Penn-Michigan State Team Develops Novel Gene Therapy for Achromatopsia". www.upenn.edu. Archived from the original on 27 October 2015. Retrieved 4 January 2016.

[9] "Finding Cures for Visual Disorders l Products". www.agtc.com. Archived from the original on 5 January 2016. Retrieved 4 January 2016.

[10] "Collaborations". agtc.com. Retrieved 2020-03-13.

[11] Lee, Jaimy. "Applied Genetic Technologies' stock rockets on early-stage eye therapy data". MarketWatch. Retrieved 2020-02-25.

[12] "AGTC Reports Encouraging Interim Six-Month Data from the Dose Escalation Cohorts of its Ongoing Phase 1/2 Clinical Trials in Achromatopsia". Applied Genetic Technologies Corporation. Retrieved 2020-03-04.

[13] "Patient Partners". agtc.com. Retrieved 2020-04-02.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]